Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome

Conditions:   Small Intestinal NET;   Carcinoid Heart Disease Interventions:   Drug: Telotristat Ethyl;   Drug: Lanreotide Sponsors:   European Organisation for Research and Treatment of Cancer - EORTC;   Ipsen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials